Side effects and complications in the use of drugs: a change historical costs body weight, dizziness, seborrheic dermatosis, vaginal bleeding, headaches, indigestion, changes in liver function tests, increased growth of Intravenous Piggyback hair, swelling of the shins. Pharmacotherapeutic group: G03GA02 - gonadotropin ovulation and historical costs stimulants historical costs . Pharmacotherapeutic group: G03DC02 - gonads historical costs and drugs used in the pathology Ointment sexual sphere. historical costs main pharmaco-therapeutic effect: stabilizing the hypothalamic-pituitary system in the menopause when the ovaries stop functioning, the central effect is due to a combination of hormonal properties of the drug (estrogenic, androgenic and weak prohestahennyh) tybolon in a daily dose of 2.5 mg inhibits the secretion of gonadotropins in postmenopausal women and inhibits ovulation in healthy women in this dose not stimulate tybolon endometrium in women post menopause, only a few patients was observed small endometrial proliferation, the degree has not increased with Hodgkin's Lymphoma time of the drug, was found as a stimulating effect historical costs the vagina, it is proved that this dose tybolonu prevents bone loss in postmenopausal, postmenopause also suppressed frustrations especially vasomotor disorders, such as hot flushes and sweating; tybolon positive impact on libido and mood. Side effects and complications by the drug: headache, nausea, vomiting, swelling of the breast, gastrointestinal disorders, disorders of menstruation, fluid retention, paresthesia, weight change, fatigue. vaginal 50 mg, 100 mg gel for external Application of 1% (0,01 g / 1 g) vaginal gel 8% Single dose applicators. Side effects and complications in the use of drugs: a bruise, pain, redness, swelling and itching, pain historical costs / or rash at the injection site preparation, generalized rash and raised body t ° c-m ovarian hyperstimulation (gastro-intestinal disorders (abdominal pain, nausea, diarrhea), chest pain, slight or moderate increase Ovarian cysts or ovaries, sometimes significant c-m hihierstymulyatsiyi ovaries can be life-threatening (large ovarian cysts (prone to rupture), development of ascites, increased body weight hidrotoraks, thromboembolic events). Indications for use drugs: menopausal c-m. / day; social status is reached within a few weeks, but best results are observed in treatment for at least 3 months at the recommended dose of admission tybolonu can Nerve Conduction Test longer. Indications for use drugs: premenstrual c-m mastodynia, menstrual disorder, accompanied by reduction in the secretory phase, dysfunctional uterine bleeding, cystic glandular endometrial hyperplasia, adenomioma uterus, endometriosis, prevention and suppression of lactation; disorders and dysfunctional bleeding during menopause. Dosing and Administration of drugs: when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / day from 16 th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic -glandular hyperplasia of endometrium (functional nature here the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - 5 - historical costs mg / day for 6 Single Protein Electrophoresis 12 days to prevent rebleeding - 5 - 10 mg / day appoint the 16 th to 25 th day of the menstrual cycle, usually in combination with estrogen drug, with endometriosis, historical costs adenomiomi-5 mg / day of 5 th to 25 th day of each cycle during 6 months to historical costs bleeding mizhmenstrualnyh, possible historical costs use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within historical costs - 3 weeks of historical costs cycle to increase the dose Polycystic Ovary 5 mg (Treatment for 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days historical costs 10 mg for cessation of breastfeeding - from 1 to 3-day take in a daily dose of 20 mg of 4-th on day 7 in a daily dose - 15 mg of 8-to 10-day - in a daily dose of 10 mg of dysfunctional disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 days in the second half of the cycle in the event of failure of historical costs therapy to the treatment regimen, adding ethinylestradiol. 2,5 mg. Method of production of drugs: powder for Mr injection of 250 mg, lyophilized powder for preparation of district for injection 1500 IU, 000 IU for 2, 5 000 IU in amp.
No comments:
Post a Comment